Cargando…

Considering the Promise of Vamorolone for Treating Duchenne Muscular Dystrophy

This commentary provides an independent consideration of data related to the drug vamorolone (VBP15) as an alternative steroid proposed for treatment of Duchenne muscular dystrophy (DMD). Glucocorticoids such as prednisone and deflazacort have powerful anti-inflammatory benefits and are the standard...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grounds, Miranda D., Lloyd, Erin M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657680/ https://www.ncbi.nlm.nih.gov/pubmed/37927274 http://dx.doi.org/10.3233/JND-230161

Ejemplares similares

Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function
por: Hoffman, Eric P., et al.
Publicado: (2019)

Efficacy and Safety of Vamorolone vs Placebo and Prednisone Among Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial
por: Guglieri, Michela, et al.
Publicado: (2022)

Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial
por: Mah, Jean K., et al.
Publicado: (2022)

Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study
por: Smith, Edward C., et al.
Publicado: (2020)

Vamorolone improves Becker muscular dystrophy and increases dystrophin protein in bmx model mice
por: McCormack, Nikki M., et al.
Publicado: (2023)

Nitric Oxide (NO) and Duchenne Muscular Dystrophy: NO Way to Go?
por: Timpani, Cara A., et al.
Publicado: (2020)

Biomarkers for Duchenne muscular dystrophy: myonecrosis, inflammation and oxidative stress
por: Grounds, Miranda D., et al.
Publicado: (2020)

IL-6 Blockade as a Therapeutic Approach for Duchenne Muscular Dystrophy
por: Mammen, Andrew L., et al.
Publicado: (2015)

Extending Life in Duchenne Muscular Dystrophy: Implications for Appraisals of Cost-Effectiveness
por: Landfeldt, Erik
Publicado: (2018)

Treating Duchenne Muscular Dystrophy: The Promise of Stem Cells, Artificial Intelligence, and Multi-Omics
por: Vera, Carlos D., et al.
Publicado: (2022)

Another Rush to Judgment: The Imaginary Worlds of ICER and Recommendations in Duchenne Muscular Dystrophy
por: Langley, Paul C
Publicado: (2019)

Lifetime Care of Duchenne Muscular Dystrophy
por: MacKintosh, Erin W., et al.
Publicado: (2020)

Levels of inflammation and oxidative stress, and a role for taurine in dystropathology of the Golden Retriever Muscular Dystrophy dog model for Duchenne Muscular Dystrophy
por: Terrill, Jessica R., et al.
Publicado: (2016)

Newborn screening for Duchenne muscular dystrophy‐early detection and diagnostic algorithm for female carriers of Duchenne muscular dystrophy
por: Gruber, Dorota, et al.
Publicado: (2022)

Mouse models for muscular dystrophies: an overview
por: van Putten, Maaike, et al.
Publicado: (2020)

Rationale for treating oedema in Duchenne muscular dystrophy with eplerenone
por: LEHMANN-HORN, FRANK, et al.
Publicado: (2012)

Survival in Duchenne muscular dystrophy
por: RALL, SUSANNE, et al.
Publicado: (2012)

Theragnosis for Duchenne Muscular Dystrophy
por: Luce, Leonela, et al.
Publicado: (2021)

Dystropathology Increases Energy Expenditure and Protein Turnover in the Mdx Mouse Model of Duchenne Muscular Dystrophy
por: Radley-Crabb, Hannah G., et al.
Publicado: (2014)

Efficacy of vamorolone in treatment of Duchene muscle dystrophy. A meta-analysis
por: Elhalag, Rowan H., et al.
Publicado: (2023)

CRISPR-Cas9-mediated exon skipping as a cardioprotective strategy in Duchenne muscular dystrophy
por: Wilton-Clark, Harry, et al.
Publicado: (2023)

A Roadmap to Newborn Screening for Duchenne Muscular Dystrophy
por: Al-Zaidy, Samiah A., et al.
Publicado: (2017)

Skeletal disproportion in glucocorticoid-treated boys with Duchenne muscular dystrophy
por: Kao, Kung-Ting, et al.
Publicado: (2019)

Cardiac therapies for Duchenne muscular dystrophy
por: Shah, Md Nur Ahad, et al.
Publicado: (2023)

Hypokalemia complicating Duchenne muscular dystrophy.
por: McDonald, B., et al.
Publicado: (1987)

The role of fibrosis in Duchenne muscular dystrophy
por: KLINGLER, WERNER, et al.
Publicado: (2012)

Delay in Diagnosis of Duchenne Muscular Dystrophy
por: Rao, Vamshi K., et al.
Publicado: (2015)

Circulating Biomarkers for Duchenne Muscular Dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2015)

Targeting angiogenesis in Duchenne muscular dystrophy
por: Podkalicka, Paulina, et al.
Publicado: (2019)

Regenerative biomarkers for Duchenne muscular dystrophy
por: Guiraud, Simon, et al.
Publicado: (2019)

Eteplirsen in the treatment of Duchenne muscular dystrophy
por: Lim, Kenji Rowel Q, et al.
Publicado: (2017)

Nutritional Challenges in Duchenne Muscular Dystrophy
por: Salera, Simona, et al.
Publicado: (2017)

The Duchenne muscular dystrophy gene and cancer
por: Jones, Leanne, et al.
Publicado: (2020)

CRISPR Therapeutics for Duchenne Muscular Dystrophy
por: Erkut, Esra, et al.
Publicado: (2022)

Exon-Skipping in Duchenne Muscular Dystrophy
por: Takeda, Shin’ichi, et al.
Publicado: (2021)

Gene Therapy for Duchenne Muscular Dystrophy
por: Elangkovan, Nertiyan, et al.
Publicado: (2021)

Family reflections: Duchenne Muscular Dystrophy
por: Gill, Omaira
Publicado: (2022)

A Blood Biomarker for Duchenne Muscular Dystrophy Shows That Oxidation State of Albumin Correlates with Protein Oxidation and Damage in Mdx Muscle
por: Al-Mshhdani, Basma A., et al.
Publicado: (2021)

Gastrointestinal Dysfunction in Patients with Duchenne Muscular Dystrophy
por: Lo Cascio, Christian M., et al.
Publicado: (2016)

Presence of mechanical dyssynchrony in duchenne muscular dystrophy
por: Hor, Kan N, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ost8lh99l59as3l2cj2hv5b886